甲状腺癌分子生物学的最新进展及其临床意义。
Recent advances in molecular biology of thyroid cancer and their clinical implications.
作者信息
Xing Mingzhao
机构信息
Department of Medicine and Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
出版信息
Otolaryngol Clin North Am. 2008 Dec;41(6):1135-46, ix. doi: 10.1016/j.otc.2008.07.001.
Abstract
Thyroid cancer is the most common endocrine malignancy. With a rapidly rising incidence in recent years, novel efficient management strategies are increasingly needed for this cancer. Remarkable advances have occurred in understanding several major biologic areas of thyroid cancer, including the molecular alterations for the loss of radioiodine avidity of thyroid cancer, the pathogenic role of the MAP kinase and PI3K/Akt pathways and their related genetic alterations, and the aberrant methylation of functionally important genes in thyroid tumorigenesis and pathogenesis. These exciting advances provide unprecedented opportunities for the development of molecular-based novel diagnostic, prognostic, and therapeutic strategies for thyroid cancer.
摘要
甲状腺癌是最常见的内分泌恶性肿瘤。近年来其发病率迅速上升，因此越来越需要针对这种癌症的新型有效管理策略。在理解甲状腺癌的几个主要生物学领域方面已经取得了显著进展，包括甲状腺癌碘摄取能力丧失的分子改变、MAP激酶和PI3K/Akt信号通路的致病作用及其相关基因改变，以及甲状腺肿瘤发生和发病机制中功能重要基因的异常甲基化。这些令人振奋的进展为开发基于分子的甲状腺癌新型诊断、预后和治疗策略提供了前所未有的机会。
相似文献
1
Recent advances in molecular biology of thyroid cancer and their clinical implications.甲状腺癌分子生物学的最新进展及其临床意义。
Otolaryngol Clin North Am. 2008 Dec;41(6):1135-46, ix. doi: 10.1016/j.otc.2008.07.001.
2
A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.一个迷你综述：MAPK/ERK 和 PI3K/Akt 通路在甲状腺滤泡细胞源性肿瘤中的作用。
Front Biosci (Landmark Ed). 2011 Jan 1;16(2):422-39. doi: 10.2741/3696.
3
Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.抑制BRAF/MEK/MAP激酶途径可恢复表达V600E BRAF突变体的甲状腺细胞中碘代谢基因的表达。
Clin Cancer Res. 2007 Feb 15;13(4):1341-9. doi: 10.1158/1078-0432.CCR-06-1753.
4
Gene methylation in thyroid tumorigenesis.甲状腺肿瘤发生中的基因甲基化
Endocrinology. 2007 Mar;148(3):948-53. doi: 10.1210/en.2006-0927. Epub 2006 Aug 31.
5
E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.E26 转化（ETS）特异性相关转录因子 3（ELF3）协调一个正反馈回路，该回路持续激活 MAPK/Erk 通路以驱动甲状腺癌。
Oncol Rep. 2019 Jan;41(1):570-578. doi: 10.3892/or.2018.6807. Epub 2018 Oct 18.
6
Molecular pathogenesis and mechanisms of thyroid cancer.甲状腺癌的分子发病机制及机制。
Nat Rev Cancer. 2013 Mar;13(3):184-99. doi: 10.1038/nrc3431.
7
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.甲状腺癌中磷脂酰肌醇-3-激酶/蛋白激酶 B 通路的遗传改变。
Thyroid. 2010 Jul;20(7):697-706. doi: 10.1089/thy.2010.1646.
8
DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.甲状腺乳头状癌中 MAPK 信号抑制基因的 DNA 甲基化。
Anticancer Res. 2013 Nov;33(11):4833-9.
9
[Genetic alterations in MAPK and PI3K/Akt signaling pathways and the generation, progression, diagnosis and therapy of thyroid cancer].[丝裂原活化蛋白激酶（MAPK）和磷脂酰肌醇-3激酶/蛋白激酶B（PI3K/Akt）信号通路中的基因改变与甲状腺癌的发生、发展、诊断及治疗]
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2012 Dec;29(6):1221-5.
10
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.滤泡型甲状腺乳头状癌中 RAS/RAF/丝裂原活化蛋白激酶和磷脂酰肌醇 3-激酶/蛋白激酶 B 信号通路的遗传改变。
Cancer. 2010 Jun 15;116(12):2974-83. doi: 10.1002/cncr.25061.
引用本文的文献
1
Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer.用于放射性碘难治性分化型甲状腺癌的酪氨酸激酶抑制剂
Life (Basel). 2023 Dec 22;14(1):22. doi: 10.3390/life14010022.
2
Immune response and mesenchymal transition of papillary thyroid carcinoma reflected in ultrasonography features assessed by radiologists and deep learning.超声特征评估的放射科医生和深度学习在甲状腺乳头状癌中的免疫反应和间充质转化。
J Adv Res. 2024 Aug;62:219-228. doi: 10.1016/j.jare.2023.09.043. Epub 2023 Oct 1.
3
Mouse Models to Examine Differentiated Thyroid Cancer Pathogenesis: Recent Updates.探讨分化型甲状腺癌发病机制的小鼠模型：最新进展。
Int J Mol Sci. 2023 Jul 6;24(13):11138. doi: 10.3390/ijms241311138.
4
Disulfiram/Cu Kills and Sensitizes -Mutant Thyroid Cancer Cells to Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways.双硫仑/铜通过依赖活性氧缓解MAPK/ERK和PI3K/AKT途径的反馈激活来杀死 - 突变甲状腺癌细胞并使其对激酶抑制剂敏感。
Int J Mol Sci. 2023 Feb 8;24(4):3418. doi: 10.3390/ijms24043418.
5
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates.颌骨坏死：甲状腺癌患者接受酪氨酸激酶抑制剂和双膦酸盐治疗的罕见但可能出现的副作用。
J Endocrinol Invest. 2021 Dec;44(12):2557-2566. doi: 10.1007/s40618-021-01634-0. Epub 2021 Jul 21.
6
Rationales for the Use of Cancer Stem Cells Markers in the Staging of Papillary Thyroid Carcinoma.甲状腺乳头状癌分期中使用癌症干细胞标志物的理论依据。
J Oncol. 2019 Jun 24;2019:1659654. doi: 10.1155/2019/1659654. eCollection 2019.
7
Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells.瘦素受体的表达及瘦素对甲状腺乳头状癌细胞的影响。
Int J Endocrinol. 2019 Feb 14;2019:5031696. doi: 10.1155/2019/5031696. eCollection 2019.
8
Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer.多酪氨酸激酶抑制剂AL3810对人甲状腺癌的体外和体内活性评估
Acta Pharmacol Sin. 2017 Nov;38(11):1533-1542. doi: 10.1038/aps.2017.107. Epub 2017 Aug 10.
9
The positive clinical therapeutically effects of Escin on advanced thyroid cancer.七叶皂苷对晚期甲状腺癌的积极临床治疗效果。
Cancer Med. 2017 May;6(5):937-943. doi: 10.1002/cam4.1031. Epub 2017 Apr 4.
10
Association between the Gene Polymorphisms and Papillary Thyroid Carcinoma in a Chinese Han Population.中国汉族人群中基因多态性与甲状腺乳头状癌的关联
J Cancer. 2016 Dec 9;7(15):2420-2426. doi: 10.7150/jca.16507. eCollection 2016.
本文引用的文献
1
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.甲状腺肿瘤中PTEN基因甲基化与磷脂酰肌醇3-激酶/AKT信号通路基因改变的相关性
Cancer. 2008 Nov 1;113(9):2440-7. doi: 10.1002/cncr.23869.
2
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.BRAFV600E突变而非RET/PTC重排与甲状腺乳头状癌中甲状腺过氧化物酶和钠碘同向转运体基因的低表达相关。
Endocr Relat Cancer. 2008 Jun;15(2):511-20. doi: 10.1677/ERC-07-0130.
3
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.间变性甲状腺癌和滤泡状甲状腺癌中受体酪氨酸激酶、磷脂酰肌醇3激酶/蛋白激酶B及丝裂原活化蛋白激酶信号通路中高度普遍的基因改变
J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16. doi: 10.1210/jc.2008-0273. Epub 2008 May 20.
4
Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.DNA错配修复基因hMLH1的高甲基化及其与甲状腺乳头状癌患者淋巴结转移和T1799A BRAF突变的相关性
Cancer. 2008 Jul 15;113(2):247-55. doi: 10.1002/cncr.23548.
5
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.甲状腺乳头状癌中的BRAF突变：致病作用、分子基础及临床意义。
Endocr Rev. 2007 Dec;28(7):742-62. doi: 10.1210/er.2007-0007. Epub 2007 Oct 16.
6
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.丝裂原活化蛋白激酶激酶抑制剂CI-1040对具有BRAF或RAS突变的甲状腺癌细胞增殖和肿瘤生长的抑制作用。
J Clin Endocrinol Metab. 2007 Dec;92(12):4686-95. doi: 10.1210/jc.2007-0097. Epub 2007 Oct 2.
7
Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.无 131I 摄取的甲状腺乳头癌（PTC）的分子特征。
Clin Endocrinol (Oxf). 2008 Jan;68(1):108-16. doi: 10.1111/j.1365-2265.2007.03008.x. Epub 2007 Sep 14.
8
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.甲状腺乳头状癌中的BRAF突变会抑制参与碘代谢的基因。
J Clin Endocrinol Metab. 2007 Jul;92(7):2840-3. doi: 10.1210/jc.2006-2707. Epub 2007 May 8.
9
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.甲状腺肿瘤中磷脂酰肌醇-3-激酶/蛋白激酶B通路基因改变的高发生率及相互排斥性
J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90. doi: 10.1210/jc.2006-2019. Epub 2007 Apr 10.
10
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.BRAF V600E维持BRAF突变型甲状腺乳头状癌细胞的增殖、转化和致瘤性。
J Clin Endocrinol Metab. 2007 Jun;92(6):2264-71. doi: 10.1210/jc.2006-1613. Epub 2007 Mar 20.
Zotero 插件